Nuklearmedizinische Diagnostik und Therapie des Prostatakarzinoms: Wer braucht wann ein PSMA-PET? Gibt es einen Stellenwert für die PSMA-Therapie?

The PSMA-PET/CT imaging has become firmly established in the diagnostics, especially in recurrency situations, due to the precise imaging of the tumor spread and is already firmly anchored in several national and international guidelines. In a single examination it enables information to be obtained on the tumor situation in the prostate bed and on potential lymph node, visceral and osseous metastases, which are necessary for increasingly personalized treatment strategies. The PSMA treatment already represents—despite the lack of approval to date—an additional treatment with few side effects in metastatic castration-resistant prostate cancer, which can significantly improve the patients’ quality of life and increase survival time without relevant toxicity. Its potential for the future also in combination with other treatment methods is not by any means foreseeable. This article addresses the applications of PSMA-PET imaging as a basis for successful treatment as well as the current status regarding indications, implementation and development of PSMA treatment.